-
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma,…
-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA
•
China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton, Dickinson and Co. (BD) to develop a specialized channel for drugs and medical devices in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Under this partnership, China Resources Guangdong Pharmaceutical will capitalize on its strengths to…
-
Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA
•
Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay…
